| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1476-5381.1987.TB11384.X |
| P8608 | Fatcat ID | release_d4aapra6i5c7zocmxvxp45txy4 |
| P932 | PMC publication ID | 1853711 |
| P698 | PubMed publication ID | 2447993 |
| P5875 | ResearchGate publication ID | 20708127 |
| P2093 | author name string | Oyekan AO | |
| Rylander R | |||
| Page CP | |||
| Beijer L | |||
| Crook P | |||
| Botting J | |||
| P2860 | cites work | An industrial study of the biological effects of cotton dust and cigarette smoke exposure | Q24265318 |
| Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist | Q28574589 | ||
| Non-steroidal anti-inflammatory drugs if combined with anti-histamine and anti-serotonin agents interfere with the bronchial and platelet effects of "platelet-activating factor" (PAF-acether). | Q33484599 | ||
| Effect of platelet agonists on airway reactivity and intrathoracic platelet accumulation | Q35754957 | ||
| Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor | Q35885820 | ||
| A comparative study of the involvement of the prostaglandin H2/thromboxane A2 pathway in intravascular platelet aggregation in guinea-pigs and rats | Q36004452 | ||
| Chemotaxis of monocytes and neutrophils to platelet-derived growth factor | Q36982903 | ||
| Airway inflammation and non allergic bronchial responsiveness | Q39741129 | ||
| Endotoxins and the lung: cellular reactions and risk for disease | Q40145649 | ||
| Inhibition of phospholipase | Q40159722 | ||
| Effect of endotoxin on airway responsiveness to aerosol histamine in sheep | Q41607893 | ||
| Triazolodiazepines: dissociation of their Paf (platelet activating factor) antagonistic and CNS activity | Q42018117 | ||
| The effect of platelet activating factor on pulmonary beta-adrenoceptors | Q42566649 | ||
| Effects of dimethylsulfoxide (DMSO) on the oxygen paradox in perfused rat hearts. | Q42578874 | ||
| Reduction of total hemolytic complement activity with Naja haje cobra venom factor does not prevent endotoxin-induced lung injury in sheep | Q44619889 | ||
| Inhalation of endotoxin stimulates alveolar macrophage production of platelet-activating factor | Q46982553 | ||
| An in vivo model for studying platelet aggregation and disaggregation. | Q53934667 | ||
| Airway hyperresponsiveness induced by platelet-activating factor: role of thromboxane generation. | Q54432169 | ||
| The platelet in asthma. | Q54465140 | ||
| Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988 | Q58178753 | ||
| The Behaviour of Complement and Platelets in Lethal Endotoxin Shock in Rabbits | Q69302022 | ||
| Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man | Q69883641 | ||
| Is platelet activating factor (PAF) a mediator of endotoxin shock? | Q70108947 | ||
| CV-3988 - a specific antagonist of platelet activating factor (PAF) | Q70428889 | ||
| Biosynthesis of Paf-acether (platelet-activating factor). VII. Precursors of Paf-acether and acetyl-transferase activity in human leukocytes | Q71395787 | ||
| Is mild byssinosis associated with small airways disease? | Q71824839 | ||
| The effect of the stable prostacyclin analogue ZK 36374 on experimental coronary thrombosis in the pig | Q72751954 | ||
| Morphometric changes of the lung induced by inhaled bacterial endotoxin | Q93647061 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endotoxins | Q319997 |
| P304 | page(s) | 803-808 | |
| P577 | publication date | 1987-12-01 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | The involvement of platelet activating factor in endotoxin-induced pulmonary platelet recruitment in the guinea-pig | |
| P478 | volume | 92 |
| Q38204987 | Acute and long-term pulmonary effects of platelet-activating factor |
| Q36980962 | Animal models for testing anti-inflammatory drugs for treatment of bronchial hyperreactivity in asthma |
| Q33379592 | Biochemical pharmacology of platelet-activating factor (and paf antagonists) in relation to clinical and experimental thrombocytopenia |
| Q38627145 | Hetrazepines as antagonists of platelet activating factor |
| Q33412283 | Important role of platelets in modulating endotoxin-induced lung inflammation in CFTR-deficient mice |
| Q28195590 | In vivo platelet response to lipopolysaccharide in mice: proposed method for evaluating new antiplatelet drugs |
| Q37057900 | Involvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists |
| Q33414226 | Lipoxin A4 and platelet activating factor are involved in E. coli or LPS-induced lung inflammation in CFTR-deficient mice |
| Q34573417 | Occupancy of platelet receptors for platelet-activating factor in patients with septicemia |
| Q28609461 | PAF. A review of its effects, antagonists and possible future clinical implications (Part II) |
| Q37885574 | Preclinical and clinical pharmacology of platelet-activating factor receptor antagonists |
| Q91983036 | Radiolabelling and immunohistochemistry reveal platelet recruitment into lungs and platelet migration into airspaces following LPS inhalation in mice |
| Q36395147 | Recent progress in ginkgolide research |
| Q92110778 | Serum cytokines and clinical features in patients with fever and thrombocytopenia syndrome |
Search more.